Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Redicran
- Development stage
- Unknown
- Lead developer
- Indena
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Redicran is a standardized cranberry extract capsule product supplied by Indena SpA and utilized in clinical research conducted by the University of Oxford. Each capsule contains 18 mg of proanthocyanidins (PAC), which are the primary active components derived from cranberry. The product is designed to treat or prevent acute, uncomplicated urinary tract infections (UTIs) by inhibiting the adhesion of uropathogenic Escherichia coli (E. coli) to the urothelium (bladder lining). By preventing bacterial attachment, Redicran aims to reduce the severity and duration of UTI symptoms, potentially serving as an adjunct or alternative to traditional antibiotic therapy. It has been studied in UK primary care settings as part of pragmatic randomized trials investigating immediate versus delayed antibiotic strategies.
- Brand names
- Redicran
- Other names
- cranberry extract
02
Targets
Uropathogenic Escherichia coli early biofilm formation machineryFimH (Type 1 fimbrial adhesin)Uropathogenic Escherichia coli SOS response and SulA-mediated filamentation pathwayP fimbriaeUropathogenic Escherichia coli flagellar apparatus (UPEC flagellum)
Beyond the preview
Go deeper on Redicran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Redicran.